CAR-T cell therapy for breast cancer: Current status and future perspective
Giuseppe Buono(Federico II University Hospital), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Margherita Tafuro(University of Naples Federico II), Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Monica Capozzi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annarita Verrazzo(Scuola Superiore Meridionale), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michela Piezzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Stefania Cocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandra Calabrese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia Calderaio(University of Naples Federico II), Claudia Martinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Martina Pagliuca(Institut Gustave Roussy)
Cited by 24
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282